Get startedLog in
    Picture of TC Biopharm (Holdings) logo

    TCBPY — TC Biopharm (Holdings) News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapValue Trap
    All News

    Brief: TC Biopharm Begins Dosing Phase 2B Clinical Study Evaluating Its Lead Compound, Omnimmune®

    Picture of TC Biopharm (Holdings) logoTC Biopharm (Holdings)
    22/11/2022 13:06
    Nov 22 (Reuters) - 
  
    * TC BIOPHARM BEGINS DOSING PHASE 2B CLINICAL STUDY
EVALUATING ITS
LEAD COMPOUND, OMNIMMUNE®, IN PATIENTS WITH ACUTE MYELOID
LEUKEMIA

Source text for Eikon:  ID:nPn6f0jKTa 
 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on TC Biopharm (Holdings)

    See all news